Skip to main content

Table 4 Logistic regression of possible risk factors and skin rashes.

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Factors Odd Ratios 95% confidence interval Pvalue
Female gender 1.26 0.67–2.39 0.470
Body weight 1.02 0.98–1.05 0.347
Baseline CD4 cell count 1.00 0.99–1.01 0.873
Receiving anti-tuberculous drugs 2.96 1.04–8.47 0.043
Receiving fluconazole 1.56 0.79–3.08 0.201
Receiving Cotrimoxazole 1.21 0.68–2.91 0.594